CHROMEDX: Resume Trading
(firmenpresse) -
CHROMEDX: Resume Trading
November 28, 2014 - ChroMedX Corp. (the Company) (CSE: CHX, OTC: MNLIF, Frankfurt: EIY2), wishes to announce that the trading of the shares of the company will be reinstalled after the previous announced trading halt. An announcement has been made. The announcement can be found here: https://www.newsfilecorp.com/release/12776/ChroMedX-Acquires-Automated-Ultrafiltration-Immunoassay-Technology#.VHjinjGG_HU
About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Companys issued US and pending international patents, dealing with blood collection, analysis and plasma/serum processing.
Follow ChroMedX Corp.:
Website: www.chromedx.com
Facebook: facebook.com/chromedxcorpTwitter: www.twitter.com/Chromedxcorp
Investor Enquiries:
W. Clark KentCorporate Development
647-519-2646ckent(at)chromedx.com
CHROMEDX CORP
Suite 520 - 65 Queen Street West
Toronto, Ontario
M5H 2M5
CSE:CHX - OTC: MNLIF
Büro: 647-872-9982
Tel (gebührenfrei)/Fax: 1-844-247-6633
E-Mail: info(at)ChroMedX.com -
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Companys control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Companys filings with Canadian securities regulators, which filings are available at www.sedar.com
Leseranfragen:
ChroMedX Corp. ist ein Medizintechnikunternehmen, das auf die Entwicklung neuartiger medizinischer Geräte für die In-vitro-Diagnostik und Point-of-Care-Untersuchungen spezialisiert ist. Die Geräte sind durch die in den USA erteilten und auf globaler Ebene schwebenden Patente, die die Blutentnahme und –untersuchung sowie die Plasma-/Blutserumverarbeitung betreffen, geschützt.
" alt="CHROMEDX: Trading Halt">
" alt="ChroMedX Acquires Automated Ultrafiltration Immunoassay Technology">
Datum: 28.11.2014 - 22:20 Uhr
Sprache: Deutsch
News-ID 355983
Anzahl Zeichen: 3138
contact information:
Town:
Wien
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 188 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CHROMEDX: Resume Trading
"
steht unter der journalistisch-redaktionellen Verantwortung von
ChroMedX Corp. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
